Frequency and Clinicohematologic Characteristics of MPL W515 Mutations in Patients with Myeloproliferative Neoplasms
Laboratory Medicine Online
; : 1-1, 2015.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-148924
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
Recently, myeloproliferative leukemia (MPL) W515 mutations have been reported to be molecular markers for myeloproliferative neoplasms (MPNs). We studied the association between MPL W515 mutations and the clinico-hematological features of patients with MPNs.METHODS:
Our study included 154 consecutive patients diagnosed with MPNs (31 had polycythemia vera [PV]; 106, essential thrombocythemia [ET]; and 17, primary myelofibrosis [PMF]). MPL W515 mutations were detected by real-time PCR and direct sequencing methods.RESULTS:
The MPL W515L mutation was found in 4 patients and the MPL W515A mutation was detected in 1 patient. These 5 patients were diagnosed with JAK2 V617F-negative ET, and they accounted for 12.5% of patients with JAK2 V617F-negative ET. The patients with MPL W515-positive ET showed significantly lower hemoglobin levels and WBC counts than did patients with MPL W515-negative ET or JAK2 V617F-positive ET.CONCLUSIONS:
MPL W515 mutation is a useful diagnostic marker for JAK2 V617F-negative MPNs and it is associated with specific hematologic characteristics such as lower hemoglobin levels and WBC counts.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Polycythemia Vera
/
Leukemia
/
Janus Kinase 2
/
Primary Myelofibrosis
/
Real-Time Polymerase Chain Reaction
/
Thrombocythemia, Essential
Limits:
Humans
Language:
Korean
Journal:
Laboratory Medicine Online
Year:
2015
Document type:
Article